VistaGen Therapeutics Faces Securities Suits Alleging Misleading PALISADE‑3 Trial Disclosures

VistaGen Faces Multiple Securities Claims Over Trial Communications

Allegations Focus on PALISADE‑3 Disclosure Practices

Several law firms are bringing securities class actions against VistaGen Therapeutics, centring on the company’s public communications about its Phase 3 PALISADE‑3 trial of intranasal fasedienol for acute social anxiety disorder. The complaints allege VistaGen repeatedly conveyed an overly positive outlook for PALISADE‑3 while concealing material risks and adverse information about the study’s prospects. Plaintiffs contend those representations created a false impression that the study was likely to succeed on its primary and meaningful secondary endpoints.

The complaints assert that the company’s statements misrepresented or omitted that PALISADE‑3 would meet its primary endpoint — change on the Subjective Units of Distress Scale — and that meaningful secondary endpoints would show treatment benefit. The filings cite a December 17, 2025 company announcement revealing PALISADE‑3 did not demonstrate a statistically significant improvement on the primary endpoint and showed no treatment difference on secondary endpoints. Plaintiffs frame the January–December 2025 communications as central to claims under Sections 10(b) and 20(a) of the Securities Exchange Act and SEC Rule 10b‑5.

The litigation raises issues beyond damages, including scrutiny of how biotech companies communicate interim and confirmatory trial expectations to investors and the market. For VistaGen, the suits increase legal and reputational pressure on its clinical development programme for fasedienol and could prompt renewed investor and regulator attention to trial design, data disclosure practices and the company’s forward‑looking statements. The proceedings may also affect how VistaGen manages stakeholder communication during ongoing and future studies.

Parallel Litigation Filings

Levi & Korsinsky, The Schall Law Firm and DJS Law Group each announce actions on behalf of investors, alleging similar misstatements and omissions connected to PALISADE‑2 and PALISADE‑3 results. The filings cover the same class period from April 1, 2024 through December 16, 2025 and assert investors suffered losses when the company disclosed the PALISADE‑3 outcome.

Lead‑Plaintiff Deadline and Next Steps

Potential class members are notified of a March 16, 2026 deadline to move the court to be appointed lead plaintiff, though appointment is optional for participation in any recovery. Firms caution the class is not yet certified, and they invite affected investors to contact them for further information as litigation proceeds.